AbCellera Cuts Hot Flashes 83% With a Single Shot — and Cashes In on the Data

AbCellera Biologics Inc. (NASDAQ: ABCL) delivered the strongest vasomotor symptom data the menopause field has produced, and Wall Street repriced the stock within hours. The Vancouver-based clinical-stage biotech announced positive top-line Phase 2 results for ABCL635, its investigational neurokinin 3 receptor (NK3R) antagonist antibody, and the trial cleared both primary efficacy endpoints after a single subcutaneous dose. Investors responded immediately: shares jumped 34.78% to close at $9.34, touched an intraday high of $10.01, and hit a three-year peak. The rally has held since, with the stock closing at $12.50 on August 25.

Key Points

• ABCL635 slashed hot-flash frequency by 83% at week four versus 33% for placebo — a 50-point spread, and a mean 8.8 fewer moderate-to-severe episodes per day (p<0.001).
• Severity fell 58% against 12% for placebo, and statistical significance held from week one onward.
• One 600 mg subcutaneous dose drove the entire four-week result, positioning ABCL635 against daily small-molecule pills.
• Safety came in clean: no serious adverse events, no severe adverse events, and no discontinuations.
• Analysts moved fast — Truist raised its target to $30 from $12, JonesResearch to $25 from $13, and Benchmark upgraded to Buy.
• AbCellera (NASDAQ: ABCL) priced an oversubscribed $200 million offering three days after the readout, adding cash to fund the program.
• Twelve-week Phase 2 data remain outstanding and represent the next real catalyst — and the next real risk.

How AbCellera Ran the Trial

AbCellera enrolled 92 postmenopausal women who averaged roughly 10 moderate-to-severe hot flashes per day, then randomized them 1:1 to receive either one 600 mg subcutaneous dose of ABCL635 or placebo. The company ran the study as a randomized, double-blind, placebo-controlled, multicenter trial.

At week four, the treatment arm recorded a mean reduction of 8.8 moderate-to-severe episodes per day from baseline. Placebo managed 3.5. That gap produced a placebo-adjusted treatment difference of 5.3 (p<0.001). Expressed as a percentage, ABCL635 cut episode frequency by 83% while placebo cut it by 33%.

Severity moved just as decisively. ABCL635 drove a mean 1.4-point reduction in severity score against 0.3 for placebo, yielding an adjusted difference of 1.1 (p<0.001) — or 58% versus 12%. Notably, statistical significance held from week one straight through week four rather than emerging late.

Participants also reported meaningful gains in sleep scores and patient global impression of change. Those secondary measures carry weight, because they determine whether a symptom drug actually improves daily life or merely moves a number on a chart.

Why the Tolerability Profile Changes the Competitive Math

Across the four-week treatment period, AbCellera recorded no serious adverse events, no severe adverse events, and no adverse events that led to discontinuation. Headache, fatigue and injection site reaction showed up more often than in the placebo group, and nothing else did.

That profile matters more than it might appear. Approved non-hormonal small-molecule NK3R antagonists carry monitoring requirements that complicate prescribing, while hormone replacement therapy remains unavailable to millions of women for medical reasons. Consequently, a well-tolerated antibody dosed subcutaneously — potentially far less often than a daily pill — attacks both constraints at once.

“By successfully targeting the NK3 receptor with an antibody, we have demonstrated potential best-in-class vasomotor symptom relief over four weeks with a single subcutaneous dose,” said Sarah Noonberg, M.D., Ph.D., Chief Medical Officer of AbCellera.

Dr. JoAnn V. Pinkerton, M.D., Women’s Midlife Professor of Obstetrics and Gynecology at the University of Virginia School of Medicine, called the results “a new efficacy benchmark for the reduction of hot flashes both in frequency and severity.” Moreover, she added that if Phase 3 validates the finding, ABCL635 “could offer a new treatment option with a more convenient dosing regimen and potentially less toxicity.”

The Market AbCellera Is Chasing

Vasomotor symptoms affect up to 80% of women moving through menopause, and most of them rate their symptoms as moderate to severe. AbCellera estimates that roughly 12 million women in the U.S. live with moderate-to-severe VMS, and more than six million actively seek treatment. Despite that scale, no non-hormonal option has yet established itself as the standard of care — which explains why every major women’s health developer keeps circling the category.

ABCL635 also carries strategic weight beyond its own indication. It became the first program from AbCellera’s GPCR and ion channel platform to enter the clinic when dosing began in July 2025. As a result, a Phase 3-worthy outcome validates the discovery engine, not just the molecule.

How AbCellera Converted Data Into Capital

The Street reacted first. Truist lifted its price target to $30 from $12 and pointed to a risk-benefit profile it considers clearly differentiated from approved small molecules. JonesResearch raised its target to $25 from $13, citing high complete-response rates and framing ABCL635 as a potential leader in a multibillion-dollar market serving women who cannot take hormone therapy. Benchmark, meanwhile, upgraded the stock to Buy from Hold.

AbCellera then pressed the advantage. On August 13, the company priced an oversubscribed $200 million public offering — 17,435,897 common shares at $9.75 apiece, plus pre-funded warrants covering another 3,076,926 shares. Jefferies, J.P. Morgan, Cantor, UBS and BMO Capital Markets ran the books, and the offering closed August 14. Management earmarked the proceeds for the internal pipeline, with ABCL635 named first.

Partnership income strengthened the position further. AbCellera’s collaboration with Jazz Pharmaceuticals (NASDAQ: JAZZ) on next-generation T-cell engaging multispecific antibodies carries $56 million in upfront payments, and development and commercial milestones extend into the hundreds of millions per program.

What Comes Next for AbCellera 

Still, the four-week readout opens the story rather than closing it. Twelve-week Phase 2 data remain outstanding, and Truist flagged that investors need the longer profile before they can judge the full clinical picture. Durability across a complete dosing interval is the single variable that decides whether ABCL635 becomes a quarterly injection franchise or simply a strong four-week result.

Beyond that question sit Phase 3 design, regulatory dialogue, and the ordinary risk that interim data shift as trials mature. For now, however, AbCellera holds the data, the cash and the analyst coverage at the same time — a combination clinical-stage biotechs rarely assemble in a single month.